/term/bs-payables-and-accrued-expenses/STU:47N Citius Pharmaceuticals (STU:47N) Accounts Payable & Accrued
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Citius Pharmaceuticals Inc (STU:47N) » Definitions » Accounts Payable & Accrued Expense for Financial Companies

Citius Pharmaceuticals (STU:47N) Accounts Payable & Accrued Expense for Financial Companies


View and export this data going back to 2020. Start your Free Trial

What is Citius Pharmaceuticals Accounts Payable & Accrued Expense for Financial Companies?

Accounts Payable & Accrued Expense for Financial Companies only applies to insurance companies.

Citius Pharmaceuticals (STU:47N) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Citius Pharmaceuticals Inc (STU:47N) » Definitions » Accounts Payable & Accrued Expense for Financial Companies
Comparable Companies
PBYI TALS XFOR TNYA CARM ANNX TRVI BTAI XBIT INMB OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
CTXR:USA 47N:Germany
Address
11 Commerce Drive, First Floor, Cranford, NJ, USA, 07016
Website
http://www.citiuspharma.com
Citius Pharmaceuticals Inc is a biopharmaceutical company with a focus on anti-infectives in adjunct cancer care, prescription products, and stem cell therapy. It is currently advancing four proprietary product candidates: LYMPHIR for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma . Mino-Lok, which is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory distress syndrome.